Clinical trials
Hepatocellular Carcinoma Recurrent clinical trials
Below are recruiting hepatocellular carcinoma recurrent clinical trials, each written for real people, not researchers. We’re tracking 170 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07405086RecruitingPhase 4
Morning versus afternoon immunotherapy for advanced cancer
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
Portland, OregonAges 18 years+ - NCT05417932RecruitingPhase 1/Phase 2
Cell therapy for hepatitis B–related liver cancer
This Phase 1/2 study tests a lab-made cell treatment (SCG101) for people with hepatitis B–related liver cancer who have already had standard treatments. It aims to shrink tumors and improve outcomes in carefully selected patients.
New York, New YorkAges 18–70 - NCT07337421RecruitingPhase 2
Chemo infusion after liver cancer surgery to lower recurrence risk
This trial tests whether a targeted chemotherapy infusion directly into the liver's main artery (HAIC) after surgery can prevent liver cancer from coming back. It is for people with certain high-risk features, like a large tumor or cancer in blood vessels, who have had their tumor completely removed.
Yangzhou, JiangsuAges 18–75 - NCT06861114Recruiting
Urine test to detect liver cancer return after surgery
This study tests if a simple urine test can help find early signs of liver cancer coming back after surgery. Patients with early-stage liver cancer who have surgery may join to help improve follow-up care.
Guangzhou, GuangdongAges 18–75 - NCT07317414RecruitingPhase 2
Beta-alanine for advanced liver cancer
This trial tests whether beta-alanine, a natural supplement, can help people with advanced liver cancer that cannot be removed by surgery. It aims to see if the treatment can slow tumor growth and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07324824RecruitingPhase 2
Sintilimab plus bevacizumab before surgery for liver cancer
This trial tests two drugs, sintilimab and bevacizumab, given before surgery to treat liver cancer that can be removed. It's for people with a certain stage of liver cancer who haven't had other treatments.
Guangzhou, GuangdongAges 18 years+ - NCT06641713Recruiting
Comparing two liver cancer treatments for large tumors
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
Beijing, Beijing MunicipalityAges 18–75 - NCT07243691Recruiting
Different infusion times of tislelizumab after liver cancer surgery
This trial tests whether giving tislelizumab (an immunotherapy drug) at different infusion times after surgery can lower the chance of liver cancer coming back in people at high risk of recurrence.
Hangzhou, ZhejiangAges 18 years+ - NCT07239245RecruitingPhase 2
TACE plus immunotherapy for high-risk liver cancer before surgery
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
Beijing, Beijing MunicipalityAges 18–75 - NCT07219459RecruitingPhase 2
New drug combo for liver cancer after PD-1/PD-L1 treatment fails
This study tests three drugs (visugromab, nivolumab, lenvatinib) compared to a placebo plus lenvatinib for people with liver cancer (HCC) that cannot be removed or has spread, and who have already been treated with a PD-1/PD-L1 inhibitor without success. The goal is to see if the combination can help shrink tumors or slow the cancer.
Irvine, CaliforniaAges 18–100 - NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Glendale, CaliforniaAges 18–65 - NCT07154082RecruitingPhase 2
Combination therapy before surgery for liver cancer
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
Wuhan, HubeiAges 18–70 - NCT07118202Recruiting
TheraBionic device for advanced liver cancer
This trial tests a device called TheraBionic P1 for people with advanced liver cancer that has not responded to other treatments. It may be an option if you have tried at least two prior therapies or cannot take standard treatments.
Bay City, MichiganAges 22 years+ - NCT06911255RecruitingPhase 1/Phase 2
Testing two immunotherapy drugs with chemoembolization for liver cancer
This trial tests whether adding two immunotherapy drugs (tremelimumab and durvalumab) to a standard liver cancer treatment called TACE can help people with liver cancer that cannot be removed by surgery. TACE uses tiny particles to block the blood supply to the tumor and delivers chemotherapy directly to the liver.
SeoulAges 19 years+ - NCT07077356RecruitingPhase 1
mRNA vaccine for liver cancer patients awaiting transplant
This trial tests an mRNA vaccine for people with liver cancer who are waiting for a liver transplant. The vaccine is given to help control the cancer while they wait.
ChengduAges 18 years+ - NCT07064681Recruiting
AK104 plus TACE for resectable liver cancer
This trial tests whether adding an immunotherapy drug (AK104) to a standard liver cancer treatment (TACE) helps prevent the cancer from coming back after surgery. It is for people with early-stage liver cancer that can be surgically removed and who have a high risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT07027436RecruitingPhase 3
Immunotherapy plus radiation before liver cancer surgery
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
Hamilton, OntarioAges 18 years+ - NCT07014150RecruitingPhase 2
Neoadjuvant combo therapy for liver cancer before surgery
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
Beijing, Beijing MunicipalityAges 18–75 - NCT07012798RecruitingPhase 2
Sequential therapy for advanced liver cancer that may become removable
This trial tests a sequence of chemotherapy (FOLFOX), immunotherapy (durvalumab), targeted therapy (bevacizumab), and focused radiation to shrink liver tumors that are not removable now, with the goal of making them operable later.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06954116RecruitingPhase 2
Iparomlimab and Tuvonralimab before surgery for liver cancer
This trial tests two drugs given before surgery to people with liver cancer that has a high chance of coming back. The goal is to see if the drugs can shrink the tumor and lower the risk of recurrence.
Wuhan, HubeiAges 18–75 - NCT06740370Recruiting
TACE with lenvatinib and immunotherapy for ruptured liver cancer
This trial tests a combination of targeted therapy (lenvatinib), immunotherapy (PD-1 inhibitor), and a procedure called TACE (which delivers chemotherapy directly to the liver tumor) for people whose liver cancer has ruptured. The goal is to stop bleeding and shrink the tumor.
Beijing, None SelectedAges 18–75 - NCT06644937RecruitingPhase 2/Phase 3
TACE with Icaritin after surgery for high-risk liver cancer
This trial tests combining a targeted medicine (Icaritin) with a procedure that delivers chemotherapy directly to the liver (TACE) after surgery. It is for people with liver cancer who have a high chance of the cancer coming back, to see if this treatment helps prevent recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06254248RecruitingPhase 2
Safety of two cancer drugs after liver transplant
This trial tests a combination of two drugs (atezolizumab and bevacizumab) for people whose liver cancer has returned after a liver transplant and cannot be treated with surgery or other local procedures. The goal is to see if this treatment is safe for liver transplant recipients.
ClichyAges 18–90 - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+
Hear when a new Hepatocellular Carcinoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma recurrent?
- Yes. Clin2 currently lists 170 recruiting hepatocellular carcinoma recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.